Heron Therapeutics

HRTX · NASDAQ🇺🇸

Overview

Earnings Dividends Seasonality Metrics

NOV

4

Q3 2025

Reported

Reported earnings 3 months ago

Previous year: -$0.06

-66.7%

R&D expense

$2.93M

Previous year: $4.43M

-33.8%

G&A expense

$14.5M

Previous year: $13.9M

+4.1%

Sales and marketing expense

$11.6M

Previous year: $13.6M

-15.0%

Gross Profit

$27.3M

Previous year: $25.5M

+7.2%

Cash and Equivalents

$16.5M

Previous year: $18.4M

Heron Therapeutics

Unlock previous datapoints

Upgrade

Heron Therapeutics

Unlock previous datapoints

Upgrade

Heron Therapeutics Revenue by Segment

Heron Therapeutics Revenue by Geographic Location

Revenue by Segment

CINVANTI Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

SUSTOL Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

ZYNRELEF Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

APONVIE Revenue

CapyFin.com

Revenue by Geographic Location

United States Revenue

CapyFin.com

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Products

Get in Touch

Resources

Heron Therapeutics

Heron Therapeutics

Heron Therapeutics

Heron Therapeutics Revenue by Segment

Heron Therapeutics Revenue by Geographic Location

Revenue by Segment

CINVANTI Revenue

SUSTOL Revenue

ZYNRELEF Revenue

APONVIE Revenue

Revenue by Geographic Location

United States Revenue

Revenue & Expenses

Historical Earnings Impact

Avg. Return Before/After Earnings